It is a substance capable of carrying out antioxidant activity and neutralizing free radicals
Who is eligible for GLP-1 weight loss treatment
Ethics declarations Ethics approval and consent to participate This study was performed with the approval of the Ethics Committee of Harbin Institute of Technology University and carried out in compliance with the Declaration of Helsinki of the World Medical Association
Primary endpoint in expanded populations and high-risk subgroups Semaglutide versus sitagliptin Among patients with obesity and type 2 diabetes at low, moderate or high cardiovascular risk in clinical practice, the 1-year risk of the composite endpoint of myocardial infarction or stroke was 1.5% (95% CI 1.4% to 1.6%) with semaglutide compared to 1.7% (95% CI 1.6% to 1.9%) with sitagliptin
Readers should consult their healthcare professional or pharmacist for the most current information on medication availability and treatment options.
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J